Clinical Trial Update: A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating vorinostat in combination with approved cancer drugs for advanced non-small cell lung cancer (Stage IIIB/IV) was terminated; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Stage IIIB or IV Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2009-10-12